362477-34-7

Upstream product

• 622-33-3 N-benzyloxyamine 
• 78879-20-6 D-N-tert-butoxycarbonyl-1,2,3,4-tetrahydroisoquinolinoline-3-carboxylic acid 
• 41220-48-8 (3R)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2687-43-6 O-benzylhydoxylamine hydrochloride 

Downstream Products

• 362476-92-4 (3-benzyloxycarbamoyl-3,4-dihydro-1H-isoquinolin-2-yl)-(4-methoxy-phenyl)-phosphinic acid 2-biphenyl-4-yl-ethyl ester 
• 362476-88-8 (3-benzyloxycarbamoyl-3,4-dihydro-1H-isoquinolin-2-yl)-(4-methoxy-phenyl)-phosphinic acid cyclohexylmethyl ester 
• 362477-04-1 (3-benzyloxycarbamoyl-3,4-dihydro-1H-isoquinolin-2-yl)-(4-methoxy-phenyl)-phosphinic acid 2-diethylamino-ethyl ester 
• 362476-96-8 (3-benzyloxycarbamoyl-3,4-dihydro-1H-isoquinolin-2-yl)-(4-methoxy-phenyl)-phosphinic acid 2-pyridin-2-yl-ethyl ester 
• 362476-87-7 (3-benzyloxycarbamoyl-3,4-dihydro-1H-isoquinolin-2-yl)-(4-methoxy-phenyl)-phosphinic acid hexyl ester 
• 1026438-73-2 (3-benzyloxycarbamoyl-3,4-dihydro-1H-isoquinolin-2-yl)-(4-methoxy-phenyl)-phosphinic acid 3,3,3-trifluoro-propyl ester 
• 362476-94-6 (3-benzyloxycarbamoyl-3,4-dihydro-1H-isoquinolin-2-yl)-[4-(2-ethoxy-ethoxy)-phenyl]-phosphinic acid ethyl ester 
• 362476-90-2 (3-benzyloxycarbamoyl-3,4-dihydro-1H-isoquinolin-2-yl)-(4-methoxy-phenyl)-phosphinic acid phenethyl ester 
• 362477-11-0 (3R)-N-benzyloxy-2-[(RS)-(2-ethoxyethyloxy)(4-methoxyphenyl)phosphoryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide 
• 362477-17-6 (3R)-N-benzyloxy-2-[(RS)-(2,2,2-trifluoroethoxy)(4-methoxyphenyl)phosphoryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide 
• 362477-19-8 (3R)-N-benzyloxy-2-[(RS)-ethoxy(4-phenoxyphenyl)phosphoryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide 
• 1026942-08-4 (3-benzyloxycarbamoyl-3,4-dihydro-1H-isoquinolin-2-yl)-(4-methoxy-phenyl)-phosphinic acid 2,2-difluoro-ethyl ester 
• 362477-28-9 (3-benzyloxycarbamoyl-3,4-dihydro-1H-isoquinolin-2-yl)-(4-methoxy-phenyl)-phosphinic acid butyl ester 
• 362477-10-9 (3-benzyloxycarbamoyl-3,4-dihydro-1H-isoquinolin-2-yl)-(4-methoxy-phenyl)-phosphinic acid 2-fluoro-ethyl ester 

Relevant academic research and scientific papers

New strategy for antedrug application: Development of metalloproteinase inhibitors as antipsoriatic drugs

Phosphonamide-based inhibitors were synthesized and evaluated for the inhibitory activities against the shedding of epidermal growth factors, amphiregulin and heparin-binding EGF-like growth factor, that would participate in the development of psoriasis. All compounds exhibited excellent inhibitory activities for these EGF sheddings; however, they also inhibited matrix metalloproteinases (MMPs). To avoid adverse effects reported by the clinical development of MMP inhibitors, the antedrug concept was introduced. Among the phosphonamide inhibitors, the 2,2,2-trifluoroethyl ester 8d and 2,2-difluoroethyl ester 8c showed rapid decomposition in human plasma, which is an essential property for the antedrug. Topical applications of these compounds significantly suppressed TPA-induced epidermal hyperplasia in murin skin, a model of psoriasis. These results suggested that the phosphonamide-based inhibitors have a therapeutic potential for the treatment of psoriasis as an antedrug application.

New type of metalloproteinase inhibitor: Design and synthesis of new phosphonamide-based hydroxamic acids

A series of phosphonamide-based hydroxamate derivatives were synthesized, and the inhibitory activities were evaluated against various metalloproteinases in order to clarify its selectivity profile. Among the four diastereomeric isomers resulting from the